Which management strategy should be recommended for this patient's bone health?
1 Comment

  • An oncology nurse - 9 years ago

    Why wouldn't the answer be initiate calcium, vit D, get DEXA, AND start on subQ denosumab since aromatase inhibitors can cause a significant decrease in BMD within the first year of therapy? Research has shown calcium and vit D isn't enough to prevent the BMD decrease and therefore the fracture risk when patients are on AI's

Leave a Comment

0/4000 chars


Submit Comment